Fibroblast Growth Factor-23(FGF-23) And Cognitive Performance In Hemodialysis Patients

Abstract

Back ground Although cognitive impairment is common in hemodialysis patients, the etiology of and risk factors for its development remain unclear. Fibroblast growth factor 23 (FGF-23) levels are elevated in hemodialysis patients and are associated with increased mortality and left ventricular hypertrophy.Material and methods We measured FGF-23 in 85 prevalent hemodialysis patients in whom comprehensive neurocognitive testing was also performed. The cross-sectional association between patient characteristics and FGF-23 levels was assessed. Principal factor analysis was used to derive two factors from cognitive test scores, representing memory and executive function. Multivariable linear regression adjusting for age, sex, education status, and other relevant covariates was used to explore the relationship between FGF-23 and each factor.Results Mean age was 38.5±10 years, 45.9% were women. The median FGF-23 level was 39 ng/L. Younger age, low hemoglobin were independently associated with higher FGF-23 levels.High FGF-23 level were associated with high KT/V(P=0.017).There were no association between cognitive impairment and FGF-23 levels,however by multi-regression analysis higher FGF-23 were associated with low parathyroid hormone ,high hemoglobin and low score of memory function test (p=0.01).conclusion there were no association between FGF-23and cognitive impairment in hemodialysis patients. Key word Hemodialysis,cognitive impairment ,FGF-23